C-type lectin domain family 3 member BGenealiases: MCDR4 · TN · TNA
Q-omics provides the consensus-scored CLEC3B profile across patient tissues and cancer cell-line models. CLEC3B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CLEC3B is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, CLEC3B protein abundance shows 26,569 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, BLCA, and PDAC as cancer lineages where CLEC3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC3B survival associations across molecular data types. CLEC3B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC3B RNA expression–survival associations across cancer types. High CLEC3B expression shows favorable associations in HNSC, KIRC, LIHC, PAAD, LUAD and THCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CLEC3B RNA expression.
This table summarizes CLEC3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CLEC3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC3B shows lower tumor expression in BLCA, KIRP, COAD, KICH, HNSC and STAD. The BLCA box plot shows higher CLEC3B RNA expression in normal versus tumor tissue (log2 FC = −6.317, t-test p < 0.001).
This table shows molecular features associated with CLEC3B in patient tissues and cancer cell lines. In patient samples, CLEC3B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CLEC3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
